Core Viewpoint - Nektar Therapeutics (NKTR) shares experienced a significant increase of 51.1% in the last trading session, closing at $56, following the announcement of positive clinical data [1][2]. Group 1: Company Performance - The stock's recent rally was driven by positive data from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study, which evaluated rezpeg in patients with moderate-to-severe atopic dermatitis, showing durable responses across key disease measurements [2]. - The safety profile of rezpeg during the maintenance phase was consistent with that observed in the induction phase of the study [2]. - Nektar is expected to report a quarterly loss of $2.69 per share, reflecting a year-over-year decline of 19.6%, with revenues projected at $9.06 million, down 68.9% from the previous year [3]. Group 2: Market Sentiment and Estimates - The consensus EPS estimate for Nektar has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. - Nektar currently holds a Zacks Rank of 3 (Hold), while another company in the same industry, Merck KGaA, has a Zacks Rank of 2 (Buy) and finished the last trading session 1.2% higher [5][6].